Jennifer Harkins Garone
Bart Maene
Issy Gordon
Heloïse Nogues
Alia El-Yassir
Robert G. Bristow
Robert Bristow completed his PhD in Medical Biophysics and Residency in Radiation Oncology at the University of Toronto with post-graduate fellowships at Erasmus University Rotterdam, MD Anderson Cancer Centre and Massachusetts General Hospital.
Bristow joined the University of Manchester as Director of the Manchester Cancer Research Centre (MCRC) in August 2017 to develop a new cancer strategy. His research focusses on the prostate cancer genome and tumour microenvironment hypoxic tumour cell characterisation by understanding role of hypoxia in driving genetic instability and the changes in sporadic and hereditary (e.g. BRCA2) prostate cancer genomes during cancer aggression.
He co-Leads the Manchester arm of the International Alliance for Cancer Early Detection (ACED), with an interest in signatures that predict aggression in men with sporadic and hereditary prostate cancer. Rob also sits on the Alliance Executive Board (AEB).
Michael Zaiac
Michael Zaiac, MD, Head of Medical Affairs Oncology Region Europe at Novartis. Michael lead the European Medical team in Oncology, Haematology and selected rare diseases. He is developing innovative programs to identify patients better using AI and to bring trials to patients. With 28 years industry experience in Medical Affairs, launching more than 10 new Medicines across a range of therapeutic areas, early commercialization and clinical development. My clinical education is in Surgery (FRCS), Surgical Oncology, Pharmaceutical Medicine (FFPM and specialist registration) and an MBA. Michael is an elected honorary fellow of Global Medicine Development (GFMD) and elected industry observer of the EMA/EORTC Cancer Medicines Forum. I am registered as a physician in the UK and Germany.